August 2026– date –
-
Yeasen and Porton Advanced Form Strategic Alliance to Fortify CGT Supply Chain and Drive Innovation
Company Announcement China Overview Yeasen Biotechnology and Porton Advanced Solutions have established a strategic partnership aimed at fortifying the cell and gene therapy (CGT) supply chain and fostering innovation. The alliance will ... -
Immunotherapy’s Fight Against Cancer: Tumor Organoids and Bioreactors Emerge as Key Research Tools
BioSPX International Overview Immunotherapy fights cancer by empowering immune cells to identify and mount sustained responses against cancer cells, rather than directly targeting tumors with drugs or radiation. Tumor organoids are becom... -
Engineering Approaches to Modify Mesenchymal Stromal Cell (MSC) Immunomodulatory Functions: Advancing Tissue Regeneration and Clinical Application via iPSC-Derived MSCs, Cell Pre-treatment, and EV Therapeutics
PMC International Overview Engineering approaches to modify mesenchymal stromal cell (MSC) immunomodulatory functions are crucial for tissue regeneration and clinical applications. These strategies include cell pre-treatment and genetic ... -
Japan’s Healios K.K. Establishes Commercial Manufacturing System: 500L Bioreactor Operational with Minaris, Targeting 40,000 Patient Doses Annually
Healios K.K. Japan Overview Japan's Healios K.K., in its Q2 FY2026 financial results, announced the establishment of a commercial manufacturing system with Minaris and the completion of full-scale production using 50L bioreactors. Engine... -
Decentralizing CAR-T Manufacturing: Point-of-Care Production to Slash Turnaround Times and Expand Therapeutic Access
Frontiers in Immunology Switzerland Overview CAR-T cell therapy, reliant on centralized manufacturing, is resource-intensive, time-consuming, and vulnerable to logistical disruptions. Interest in decentralized or point-of-care (POC) manu... -
Transforming Cell Therapy: New Report Projects Shift to Cost-Effective Manufacturing by 2035
Roots Analysis India Overview A new report from Roots Analysis, 'Cell Therapy Manufacturing Market 2035,' predicts a critical shift towards more standardized, reproducible, and cost-effective production models. This transformation is dri... -
Off-the-Shelf CAR T Therapies Revolutionize Cancer Treatment: Simplifying Manufacturing with Healthy Donor Cells, Reducing Wait Times and Costs
Katie Couric Media USA Overview Next-generation allogeneic CAR T-cell therapy, or 'off-the-shelf CAR T,' utilizes healthy donor cells instead of patient-specific cells, enabling large-batch manufacturing and extended storage. This signif... -
Early Manufacturing Planning Critical for Commercial Success of Advanced Therapies: Ensuring Scalability from Process Design to Automation
The Medicine Maker International Overview The commercial success of advanced therapies heavily depends on meticulous manufacturing planning from the early development stages. Sponsors must assess process consistency, effective technology... -
Patient-Specific iPSCs in Organ-on-a-Chip Systems: Pioneering Personalized Medicine and Drug Testing
PMC International Overview Organ-on-a-chip (OoC) systems innovatively mimic human organ structures and functions at a micro-scale. Induced pluripotent stem cells (iPSCs) serve as an ideal platform for constructing patient-specific OoC mo... -
In Vivo CAR-T Cell Therapy Demonstrates Clinical Proof-of-Concept with AI Acceleration: Enabling Direct In-Body Immune Cell Gene Editing Towards ‘Off-the-Shelf Biologics’
OncoDaily International Overview While autologous CAR-T cell therapy yields durable remissions in B-cell malignancies, its delivery model faces persistent challenges. In vivo CAR-T emerges as a radically different approach, delivering CA...
